17th Mar 2014 10:54
LONDON (Alliance News) - Oxford Pharmascience Group PLC said Monday it has appointed a Director of research and development to manage the firms' development activities.
Dr Liz King has joined to lead and execute the company's development programme focused on the company's two main medicines reformulation programmes in NSAIDs and Statins with reduced side effects.
King will be a non-board member of the Oxford Pharmascience management team and will report to Marcelo Bravo, Chief Executive.
Shares in the firm last traded at 4.25 pence per share.
By Alice Attwood; [email protected]; @AliceAtAlliance
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Pharmascience Group